Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
PT-141 Key Research Facts: Rapid Reference 10 Things Researchers Should Know About PT-141 PT-141 Peptide is the only melanocortin receptor agonist with FDA approval for sexual dysfunction (in women, as Vyleesi) It acts centrally on the brain, not peripherally on blood vessels making it mechanistically distinct from all PDE-5 inhibitors Its primary targets are MC3R and MC4R in the hypothalamus Clinical trials involved 1,200+ premenopausal women, providing a robust safety and efficacy dataset The most common side effect is transient nausea, observed in approximately 40% of subjects PT-141 produces a temporary, dose-dependent increase in blood pressure (~6 mmHg systolic) Effects onset within 4560 minutes and can persist 1224 hours The compound was derived from Melanotan II, with the pigmentation mechanism removed PT-141 has no significant interaction with the PDE-5 enzyme it works through an entirely different pathway Research-grade PT-141 is available as a lyophilized powder requiring reconstitution with bacteriostatic water Conclusion: PT-141 (Bremelanotide) is not a peripheral compound or a trend-driven research curiosity
Dihexa has been researched for its ability to help repair brain damage and support cognitive performance, particularly in neurodegenerative conditions
Vanderah TW (Editors)
Alcohol amplifies NK-cell immune dysregulation by weakening their antiviral activity while enhancing their tissue-damaging responses
Vitamin C (ascorbyl glucoside): Supports collagen production and improves skin vitality
Expert-led care: Licensed providers oversee your treatment plan
